SPY329.02+2.50 0.77%
DIA266.48+2.13 0.81%
IXIC10,904.61+159.33 1.48%

Apyx Medical Sees PRelim. Q4 Sales $8.1M-$8.3M, Prelim. FY19 Sales $27.9M-$28.1M

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market

Benzinga · -

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported preliminary revenue results for the full year and fourth quarter ended December 31, 2019.

Preliminary Full Year 2019 Revenue Summary:

  • Total revenue from continuing operations in a range of approximately $27.9 to $28.1 million, up approximately 67% to 68% year-over-year.
    • Advanced Energy revenue in a range of approximately $22.3 to $22.6 million, up approximately 71% to 73% year-over-year.
    • OEM revenue of approximately $5.5 million, up approximately 52% year-over-year.

Preliminary Fourth Quarter 2019 Revenue Summary:

  • Total Q4 revenue from continuing operations in a range of approximately $8.1 to $8.3 million, up approximately 36% to 41% year-over-year.
    • Advanced Energy revenue of approximately $6.6 to $6.9 million, up approximately 52% to 58% year-over-year.
    • OEM revenue of approximately $1.5 million, down approximately 7% year-over-year.